<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> with <z:hpo ids='HP_0001085'>papilledema</z:hpo> occurred in two patients receiving <z:chebi fb="1" ids="4315">danazol</z:chebi> therapy for either cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> or immune <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Results of clinical, laboratory, and neuroradiologic studies showed no apparent cause for the condition in Case 1 and the <z:hpo ids='HP_0001085'>papilledema</z:hpo> resolved one month after discontinuing <z:chebi fb="1" ids="4315">danazol</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Carotid angiography in Case 2 demonstrated cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp>; the <z:hpo ids='HP_0001085'>papilledema</z:hpo> showed gradual improvement after cessation of <z:chebi fb="1" ids="4315">danazol</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>An additional seven cases of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> presumed secondary to <z:chebi fb="1" ids="4315">danazol</z:chebi> therapy have been reported to the Food and Drug Administration </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:hpo ids='HP_0001085'>papilledema</z:hpo> resolved in <z:hpo ids='HP_0000001'>all</z:hpo> seven cases soon after discontinuing <z:chebi fb="1" ids="4315">danazol</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>A drug-induced complication should be suspected, and alternative therapy sought, in patients who develop intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> associated with administration of <z:chebi fb="1" ids="4315">danazol</z:chebi> </plain></SENT>
</text></document>